tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Ravi Mehrotra, 6 are a BUY (100%).
Analyst Ravi Mehrotra, carries an average stock price target met ratio of 100% that have a potential upside of 24.9% achieved within 139 days.
Ravi Mehrotra’s has documented 12 price targets and ratings displayed on 2 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on BIIB, Biogen at 19-Nov-2014.
Analyst best performing recommendations are on BIIB (BIOGEN).
The best stock recommendation documented was for BIIB (BIOGEN) at 11/22/2013. The price target of $290 was fulfilled within 3 days with a profit of $4.38 (1.53%) receiving and performance score of 5.11.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 22-Nov-2017
$275
$97.66 (55.07%)
$225
3 days ago
(01-Apr-2026)
25/45 (55.56%)
$91.22 (49.64%)
315
Buy Since 24-Apr-2020
$245
$67.66 (38.15%)
$230
3 days ago
(01-Apr-2026)
17/32 (53.13%)
$61.22 (33.31%)
200
Hold Since 23-May-2019
$187
1 months 25 days ago
(10-Feb-2026)
30/33 (90.91%)
$-6.81 (-3.51%)
176
Buy Since 04-Mar-2022
$233
$55.66 (31.39%)
$210
1 months 26 days ago
(09-Feb-2026)
44/79 (55.7%)
$39.19 (20.22%)
130
Buy Since 10-Apr-2025
$246
$68.66 (38.72%)
1 months 26 days ago
(09-Feb-2026)
10/13 (76.92%)
$52.19 (26.93%)
355
What Year was the first public recommendation made by Ravi Mehrotra?
